

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Atherosclerosis	Chemokine CC motif ligand 17 (CCL17)	<p>Mouse studies suggest antagonizing CCL17 could help treat atherosclerosis. In a mouse model of atherosclerosis, <i>Ccl17</i> deficiency resulted in lower plaque formation and aortic macrophage levels than <i>Ccl17</i> expression. In the same mouse model, an anti-CCL17 antibody decreased lesion formation and macrophage levels compared with an isotype control. Next steps include identifying the receptor of CCL17 that leads to the therapeutic effects.</p> <p>SciBX 4(23); doi:10.1038/scibx.2011.656 Published online June 9, 2011</p>	Patent application filed covering findings; available for licensing	<p>Weber, C. <i>et al.</i> <i>J. Clin. Invest.</i>; published online June 1, 2011; doi:10.1172/JCI44925</p> <p>Contact: Alma Zerneck, University of Wuerzburg, Wuerzburg, Germany e-mail: alma.zerneck@virchow.uni-wuerzburg.de</p> <p>Contact: Christian Weber, Aachen University, Aachen, Germany e-mail: christian.weber@med.uni-muenchen.de</p>